Literature DB >> 15120775

The compatibility and stability of midazolam and dexamethasone in infusion solutions.

Phillip D Good1, Jennifer J Schneider, Peter J Ravenscroft.   

Abstract

The delivery of subcutaneous medication by continuous infusion is common in palliative medicine. Many centers combine multiple medications, but the analytical confirmation of the compatibility and stability of these combinations has rarely been performed. This study examined the compatibility and stability of midazolam and dexamethasone using high performance liquid chromatography. Nine different solutions were prepared in polypropylene syringes by combining these two drugs with 0.9% sodium chloride. When these two drugs were combined in a syringe, there was significant loss of midazolam over 48 hours, with only 60-80% of the initial concentration remaining in syringes stored at 35-39 degrees C. This study demonstrates that cloudiness of a solution is not the only predictor of drug loss and that drug loss may occur even in solutions that remain clear at time of preparation. The clinical implications of these results are that dexamethasone and midazolam should not be combined in syringe driver solutions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120775     DOI: 10.1016/j.jpainsymman.2004.02.002

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  4 in total

1.  Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.

Authors:  María Espinosa-Bosch; Fuensanta Sanchez-Rojas; Catalina Bosch-Ojeda
Journal:  Eur J Hosp Pharm       Date:  2018-01-27

2.  Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration.

Authors:  Bao-Xia Fang; Fu-Chao Chen; Dan Zhu; Jun Guo; Lin-Hai Wang
Journal:  Oncotarget       Date:  2017-10-31

Review 3.  The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review.

Authors:  James Baker; Andrew Dickman; Stephen Mason; John Ellershaw
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

4.  Therapeutic Treatment Plan Optimization during the COVID-19 Pandemic: A Comprehensive Physicochemical Compatibility Study of Intensive Care Units Selected Drugs.

Authors:  Maria Gloria Tarantini; Stéphanie Ramos; Philippe-Henri Secrétan; Laura Guichard; Lamia Hassani; Agnès Bellanger; Julien Mayaux; Patrick Tilleul; Fadwa El Kouari; Hassane Sadou Yayé
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.